Lexicon Pharmaceuticals Inc (LXRX)vsMerck & Company Inc (MRK)
LXRX
Lexicon Pharmaceuticals Inc
$1.85
-2.12%
HEALTHCARE · Cap: $835.09M
MRK
Merck & Company Inc
$120.79
-2.77%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 94336% more annual revenue ($65.77B vs $69.64M). MRK leads profitability with a 13.6% profit margin vs -37.5%. MRK earns a higher WallStSmart Score of 50/100 (D+).
LXRX
Avoid29
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LXRX.
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1572.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -12.9% — below average capital efficiency
Earnings declined 63.4%
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LXRX
The strongest argument for LXRX centers on Revenue Growth, Debt/Equity. Revenue growth of 1572.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : LXRX
The primary concerns for LXRX are Market Cap, Return on Equity, EPS Growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
LXRX profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
LXRX carries more volatility with a beta of 1.07 — expect wider price swings.
LXRX is growing revenue faster at 1572.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lexicon Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?